Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC)
Vansteenkiste, J. F.
Hui, R. N.
Dennis, P. A.
Antonia, S. J.
AffiliationDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD